| Symbol |
ATP6V0D1 |
| Full Name |
ATPase H+ Transporting V0 Subunit D1 |
| Chromosome |
16p13.3 |
| NCBI Gene |
9114 |
| Ensembl |
ENSG00000159720 |
| OMIM |
618171 |
| UniProt |
P61421 |
| Gene Type |
Protein coding |
| Protein Class |
V-ATPase subunit (V0 domain) |
| Expression |
Brain, Liver, Kidney, Ubiquitous |
ATP6V0D1 (ATPase H+ Transporting V0 Subunit D1) encodes a critical subunit of the vacuolar-type H+-ATPase (V-ATPase), a multisubunit proton pump essential for acidification of intracellular compartments throughout the cell. As the d subunit of the V0 domain, ATP6V0D1 plays a crucial role in assembling and stabilizing the membrane-embedded proton channel that drives acidification of lysosomes, endosomes, synaptic vesicles, and other acidic compartments 1.
V-ATPases are fundamental to cellular homeostasis, and their dysfunction has been increasingly recognized as a key contributor to neurodegenerative diseases. In the brain, V-ATPase-dependent acidification is essential for lysosomal degradation of protein aggregates, synaptic vesicle recycling, and autophagy—all processes that become dysregulated in conditions like Alzheimer's disease and Parkinson's disease. The ATP6V0D1 subunit, in particular, has attracted attention because of its essential role in V-ATPase assembly and its tissue-specific expression patterns that influence neuronal function 2.
| Property |
Value |
| Official Symbol |
ATP6V0D1 |
| Full Name |
ATPase H+ Transporting V0 Subunit D1 |
| Gene ID |
9114 |
| Chromosomal Location |
16p13.3 |
| Ensembl ID |
ENSG00000159720 |
| UniProt ID |
P61421 |
| OMIM |
618171 |
| Gene Type |
Protein coding |
| Protein Class |
V-ATPase subunit (V0 domain) |
| Aliases |
VATPase D subunit, V0 D1, ATP6D1 |
V-ATPases are large, multisubunit enzymes composed of two domains:
V0 Domain (Membrane-embedded):
- Forms the proton channel across the membrane
- Contains multiple subunits: a, c, c', c'', d, e (ATP6V0D1 is the d subunit)
- Responsible for proton translocation across membranes
- Consists of approximately 14 subunits in mammals
V1 Domain (Cytoplasmic):
- Contains the ATP-hydrolyzing components (A, B, C, D, E, F, G, H)
- Provides the energy for proton pumping
- Regulated by multiple mechanisms
The V0 and V1 domains are connected by a stalk structure that transmits conformational changes from the V1 ATPase to the V0 proton channel.
As the d subunit of the V0 domain, ATP6V0D1 has specific functions:
- Assembly: Essential for proper assembly of the V0 domain
- Stability: Maintains structural integrity of the proton channel
- Proton Translocation: Contributes to the structural basis of H+ transport
- V1-V0 Coupling: Facilitates communication between ATP hydrolysis and proton pumping
The d subunit sits in the center of the V0 domain, connecting the proton channel to the peripheral stalk that links to the V1 domain 3.
V-ATPases use the energy from ATP hydrolysis to pump protons against electrochemical gradients:
- ATP Hydrolysis in the V1 domain induces conformational changes
- Mechanical Transmission through the central stalk to the V0 domain
- Proton Binding at the cytosolic interface of the proton channel
- Conformational Shift moves protons through the membrane
- Proton Release at the luminal/extracellular side
This process can pump 2-4 protons per ATP hydrolyzed, creating steep proton gradients (pH differences of 1-2 units).
V-ATPase is essential for maintaining the acidic interior of lysosomes:
- Optimal Hydrolase Activity: Lysosomal enzymes function optimally at pH 4.5-5.0
- Substrate Degradation: Acidification enables breakdown of proteins, lipids, nucleic acids
- Autophagosome-Lysosome Fusion: Required for autophagic degradation
- Cargo Sorting: Acidification drives receptor recycling and trafficking
ATP6V0D1 deficiency leads to reduced lysosomal acidification and accumulation of undegraded material 4.
V-ATPase plays critical roles in autophagy:
- Autophagosome Formation: V-ATPase activity is required for early steps
- Autophagosome-Lysosome Fusion: Acidification enables fusion events
- Lysosomal Degradation: Acid-dependent hydrolases digest cargo
- Nutrient Recycling: Autophagy-derived amino acids are released to cytosol
Impaired V-ATPase function leads to:
- Accumulation of autophagosomes
- Failed protein aggregate clearance
- Cellular stress and death
In neurons, V-ATPase acidifies synaptic vesicles:
- Neurotransmitter Loading: The vesicular transporter requires electrochemical gradient
- Vesicle Recycling: Acidification enables reuse of synaptic vesicles
- Exocytosis: Proton gradient drives neurotransmitter release
- Synaptic Plasticity: Activity-dependent acidification modulates transmission
V-ATPase functions in endosomal compartments:
- Early Endosome Acidification: Required for cargo sorting
- Late Endosome Maturation: Acidification drives transition
- MHC Class II Presentation: Endosomal acidification enables antigen processing
- Receptor Downregulation: Endosomal sorting of activated receptors
ATP6V0D1 shows widespread expression:
| Tissue |
Expression Level |
| Brain |
High |
| Liver |
High |
| Kidney |
High |
| Lung |
Moderate |
| Heart |
Moderate |
| Spleen |
Moderate |
| Pancreas |
Low-Moderate |
High expression in tissues with abundant lysosomes and secretory vesicles.
Within the central nervous system:
- Neurons: High expression in various neuronal populations
- Astrocytes: Moderate expression
- Microglia: Expression in resident immune cells
- Oligodendrocytes: Lower expression
- Synaptic Terminals: Particularly high in presynaptic boutons
The expression pattern supports roles in synaptic function, autophagy, and neuronal homeostasis.
V-ATPase dysfunction is increasingly recognized in AD pathogenesis 2:
Lysosomal Impairment:
- Reduced V-ATPase activity in AD brain
- Elevated lysosomal pH (reduced acidification)
- Impaired clearance of amyloid-beta and tau
Autophagic Blockade:
- Accumulation of autophagic vacuoles
- Failed degradation of protein aggregates
- Contribution to amyloid plaque formation
Synaptic Dysfunction:
- Impaired synaptic vesicle acidification
- Altered neurotransmitter loading
- Contributes to synaptic loss
Therapeutic Implications:
- V-ATPase enhancers could improve lysosomal function
- Restoring autophagy may reduce protein aggregation
- Protecting synaptic function
V-ATPase involvement in PD is particularly relevant to alpha-synuclein pathology 5:
Lysosomal Dysfunction:
- V-ATPase activity reduced in PD models
- Impaired alpha-synuclein clearance
- Accumulation of toxic aggregates
Endosomal Impairment:
- Dysregulated endosomal trafficking
- Impaired receptor recycling
- Altered protein sorting
Mitochondrial Connections:
- V-ATPase affects mitochondrial function indirectly
- Links between lysosomal and mitochondrial dysfunction
Genetic Links:
- PD-associated genes affect V-ATPase function
- GBA, LRRK2, and other genes connect to lysosomal pathways
Amyotrophic Lateral Sclerosis (ALS):
- V-ATPase in motor neuron survival
- Autophagy impairment in ALS models
- Protein aggregate clearance defects
Huntington's Disease:
- Mutant huntingtin affects V-ATPase
- Autophagic clearance disrupted
- Lysosomal dysfunction contributes to pathology
Lysosomal Storage Disorders:
- V-ATPase deficiency causes neurodegeneration
- Models mimic lysosomal storage diseases
- Gene therapy approaches under investigation
ATP6V0D1 variants identified:
| Variant Type |
Examples |
Clinical Significance |
| Common SNPs |
rs11545682, rs3785519 |
Expression modulation |
| Rare variants |
Various |
Under investigation |
| Pathogenic |
Very rare |
Severe neurological phenotypes |
- Limited direct evidence for ATP6V0D1 variants in neurodegeneration
- Expression studies show reduced ATP6V0D1 in disease states
- Further research on genetic contributors needed
Therapeutic strategies targeting V-ATPase:
-
Activators: Small molecules to enhance V-ATPase function
- Improve lysosomal acidification
- Enhance autophagy
- Protect synaptic function
-
Inhibitors: Used in research and some clinical applications
- Bafilomycin A1: Specific V-ATPase inhibitor
- Concanamycin A: Research use
- Applications in cancer (reduced tumor metabolism)
- Selectivity: Achieving tissue-specific effects (brain vs. peripheral)
- Delivery: Blood-brain barrier penetration
- Mechanism: Balancing proton pump activity without toxicity
- Isoform Specificity: Multiple V-ATPase isoforms
- Screening for V-ATPase enhancers
- Gene therapy approaches
- Protein-protein interaction inhibitors
- Combination therapies
Key experimental approaches:
- Molecular Biology: qPCR, Western blot, knockout studies
- Cell Biology: Lysosomal pH measurements, autophagy assays
- Electrophysiology: Proton channel activity
- Live Cell Imaging: Fluorescent pH sensors, autophagy trackers
- Animal Models: Knockout mice, disease models
- Cell Lines: HEK293, neuronal cell lines
- Primary Cells: Primary neurons, astrocytes
- Animal Models: Atp6v0d1 knockout mice
- Patient Tissue: Brain samples from disease patients
¶ Interactions and Pathways
ATP6V0D1 interacts with:
- Other V0 Subunits: a, c, c', c'', e subunits
- V1 Domain Subunits: Through stalk connections
- Accessory Proteins: Assembly factors
- Lysosomal Proteins: For compartment-specific functions
ATP6V0D1 integrates with:
- mTORC1 Signaling: Lysosomal localization and nutrient sensing
- Autophagy Cascade: Upstream regulation
- ER Stress Pathways: Unfolded protein response
- Apoptosis: Connections to cell death pathways
Atp6v0d1-deficient mice:
- Embryonic Lethality: Some knockouts are lethal
- Conditional Knockouts: Brain-specific deletion possible
- Phenotypes: Lysosomal dysfunction, neurodegeneration
ATP6V0D1 in:
- AD Models: Crossbreeding with APP/PS1 mice
- PD Models: Alpha-synuclein overexpression models
- Aging Studies: Age-related lysosomal dysfunction
ATP6V0D1 is a critical component of the V-ATPase proton pump, essential for lysosomal acidification, autophagy, and synaptic function. Its dysfunction contributes to the pathogenesis of multiple neurodegenerative diseases, including Alzheimer's and Parkinson's disease. Understanding and targeting V-ATPase function represents a promising therapeutic strategy for enhancing protein aggregate clearance and protecting neuronal function.
Key points:
- ATP6V0D1 is the d subunit of the V0 domain of V-ATPase
- Essential for lysosomal acidification and autophagy
- Dysfunction contributes to AD and PD pathogenesis
- V-ATPase modulators are being developed as therapeutics
- Challenges include achieving brain-penetrant, selective compounds
- NCBI Gene: ATP6V0D1
- V-ATPase in Alzheimer's disease pathogenesis
- V-ATPase structure and mechanism
- Lysosomal acidification and disease
- V-ATPase and alpha-synuclein in Parkinson's disease
- Autophagy and neurodegeneration
- V-ATPase in synaptic function
- Lysosomal dysfunction in AD
- V-ATPase inhibitors in research
- Proton pumps in cell biology
- mTOR and lysosomal function
- Protein aggregation and autophagy
- Endosomal trafficking in neurons
- V-ATPase assembly factors
- Neurodegeneration and lysosomal storage
- Therapeutic targeting of V-ATPase
ATP6V0D1 as a biomarker:
- Expression Biomarkers: ATP6V0D1 levels in CSF as lysosomal function marker
- Genetic Testing: Rare variants may indicate susceptibility
- Imaging: Future PET ligands for V-ATPase (experimental)
Current approaches to V-ATPase-targeted therapy:
Small Molecule Activators:
- Screening for compounds that enhance V-ATPase activity
- Improving lysosomal acidification
- Restoring autophagy flux
Gene Therapy:
- AAV-mediated ATP6V0D1 overexpression
- Targeting specific neuronal populations
- Combination with other lysosomal genes
Protein Therapy:
- Engineering stable V-ATPase subunits
- Enhanced delivery methods
¶ Challenges and Limitations
- Systemic Effects: V-ATPase in all cells complicates targeting
- BBB Penetration: CNS delivery remains difficult
- Dosage Balance: Too much vs. too little activity
- Compensatory Mechanisms: Cellular adaptation
| Species |
Homolog |
Identity |
| Human |
ATP6V0D1 |
Reference |
| Mouse |
Atp6v0d1 |
97% |
| Rat |
Atp6v0d1 |
96% |
| Zebrafish |
atp6v0d1 |
85% |
| Drosophila |
Vha55 |
70% |
| C. elegans |
vha-19 |
55% |
High conservation indicates essential cellular function.
- Structural Studies: High-resolution V-ATPase structure
- Single-Cell Analysis: Understanding cell-type specificity
- In Vivo Imaging: Real-time lysosomal pH measurement
- Clinical Translation: Moving from basic to clinical
- Nanoparticle Delivery: Targeted V-ATPase modulators
- Combination Therapy: V-ATPase + other targets
- Personalized Medicine: Genetic stratification
- What is the precise role of neuronal ATP6V0D1 in disease?
- Can selective brain V-ATPase modulation be achieved?
- What determines cell-type specific vulnerability?
- How does ATP6V0D1 interact with other PD/AD risk genes?
¶ Clinical and Research Perspectives
Biomarker-driven approaches:
- Genetic Markers: ATP6V0D1 variants and disease risk
- Expression Markers: Tissue and fluid biomarker levels
- Functional Markers: Lysosomal pH measurements
- Clinical Correlates: Disease stage and progression
Current status of V-ATPase targeting:
- Discovery: High-throughput screening for activators
- Preclinical: Animal model efficacy testing
- Formulation: Brain-penetrant delivery methods
- Clinical: Early-phase trial planning
V-ATPase-targeted combinations:
- With Autophagy Modulators: Enhanced clearance
- With Antioxidants: Mitochondrial protection
- With Anti-inflammatory: Neuroprotection
- With Gene Therapy: AAV-mediated expression
For V-ATPase therapeutic development:
- Safety Assessment: Off-target effects on peripheral organs
- Dosing Strategies: Chronic vs. acute treatment
- Biomarker Endpoints: Target engagement markers
- Clinical Endpoints: Functional outcomes
Drug development costs:
- Discovery investments
- Preclinical testing
- Clinical trials
- Manufacturing scale-up
V-ATPase therapy potential:
- Alzheimer's disease treatment
- Parkinson's disease modification
- Lysosomal storage disorders
- General neuroprotection
Required resources:
- Lysosomal function assays
- Animal model systems
- Patient sample collections
- Clinical trial networks
Expertise needed:
- Biochemistry: V-ATPase biology
- Pharmacology: Drug development
- Neuroscience: Neurodegeneration
- Clinical: Trial design
¶ Funding Landscape
Support for V-ATPase research:
- NIH funding opportunities
- Foundation support
- Industry partnerships
- International collaborations
V-ATPase versus other lysosomal targets:
| Target |
Function |
Therapeutic Potential |
Challenges |
| ATP6V0D1 |
Proton pump |
High |
Selectivity |
| GBA |
Hydrolase |
Moderate |
Delivery |
| LRP1 |
Receptor |
Low-Moderate |
Specificity |
| CTSB |
Protease |
Moderate |
Specificity |
Emerging research areas:
- Structural Biology: High-resolution V-ATPase structure
- Single-Cell Analysis: Cell-type specific functions
- In Vivo Imaging: Real-time lysosomal pH monitoring
- Clinical Translation: First-in-human studies
ATP6V0D1 represents a critical therapeutic target for neurodegenerative diseases through its essential role in lysosomal acidification and autophagy. While significant challenges remain in developing brain-penetrant V-ATPase modulators, ongoing research continues to advance our understanding and move toward clinical translation.